MIT's annual "50 smart companies" unveiled Baiji, Xinda, Fosun and other companies...

Transfer from On November 19th, the MIT Technology Review released its annual list of "50 Smart Companies" (TR50). according to
, the annual list aims to focus on the important innovations that are taking place right now, anticipating the forces of innovation that will change China and the world, and that companies on the list are expected to continue to lead technology or create new disruptive forces in the next 3-5 years.
it is worth mentioning that in the field of biomedicine, we have seen a number of companies focusing on innovative drug research and development, such as Baiji Shenzhou, Xinda Bio, Fosun Pharma, Tiantian Bio.
this article, we'll show you why these companies are rated as "smart companies."
"50 Smart Companies" List Photo Source: Resources 1, Baiji Shenzhou List Reason: The company has laid out more than 30 anti-tumor drugs, 11 of which are new drugs developed for their own research.
has the first Chinese original anti-cancer drug approved for sale in the United States, BTK inhibitor Zebutini, to achieve China's original research anti-cancer new drug out to sea "zero breakthrough."
Zebtini is a small molecule Bruton tyrosine kinase (BTK) inhibitor designed to maximize target occupancy and minimize off-target effects.
November 2019, the product was approved in the United States for patients with block cell lymphoma (MCL).
, it was approved in China for use in patients with chronic lymphocytic leukemia/small lymphocyte lymphoma (CLL/SLL) and MCL.
currently, global development projects for the product are advancing, with new adaptation applications for the treatment of Fahrenheit globulinemia (WM) being accepted in China and included in priority reviews.
according to the MIT Technology Review, Baiji Shenzhou is currently one of the largest clinical trials in the world, with more than 70 clinical trials under way, 10 of which are phase 3 clinical trials worldwide.
Zebtini, its self-developed PD-1 inhibitor, Reilly Pearl Monoanti, has also been launched in China.
in the study of PARP1/2 inhibitor Parmipali and targeted GD2 Dittosi monoantigen have submitted registration applications in China and have been included in the priority review.
addition, there are a number of independent research and development of innovative products are being developed, targeting TIGIT, Bcl-2, OX40, HPK1 and so on.
2, the reason for the list: The company has the first and only PD-1 single anti-drug Xindili single anti-injection liquid entering China's health insurance list, to promote oncology immunotherapy to benefit more Chinese patients.
according to the award speech, the price of 100 mg xindili mono-resistance after the inclusion of medical insurance is only 2843 yuan, and the comprehensive one-year treatment cost after medical insurance reimbursement is only 29,000 yuan.
was approved in China at the end of 2018 for the treatment of relapsed/refractic classic Hodgkin's lymphoma (cHL).
cHL is a major category of malignant lymphoma, the annual incidence rate of 1/10-4/100,000 population, clinical standard treatment is self-hematopoietic stem cell transplantation.
, however, many patients are unable to receive such treatment due to a variety of factors.
according to Xinda Bio Financial Report, Xindili single anti-injection liquid listed in less than a year to break the sales revenue mark of 1 billion yuan, the first three quarters of this year's cumulative sales of more than 1.5 billion yuan.
this partly reflects the clinical need for the new drug.
Currently, two new adaptation applications for non-squamous non-small cell lung cancer (NSCLC) first-line treatment and squamous NSCLC first-line treatment have been submitted in China and have obtained three orphan drug qualifications outside China.
According to publicly available information, Cinda Bio is promoting more than 20 clinical trials in China and the United States, including 8 registered clinical studies covering liver, lung, stomach, esophageal and other cancers.
3, the reason for Jun's list: As China's first intestinal microbial AI pharmaceutical company, unknown Jun through the intestinal microbiome as a biomarker prediction model, for cancer patients to receive PD-1 treatment prediction accuracy has reached the international leading level.
awards speech pointed out that unknown Jun has more than 340,000 microbial and disease-related data, combined with self-research machine learning algorithms, can accurately predict the composition of the bacteria on the host gene level regulation, guide drug research and development and clinical application.
years, intestinal micro-ecological pharmaceutical has become a hot research field in the pharmaceutical industry.
study shows that the gut microbiome plays an important role in the occurrence and progression of a variety of diseases, such as inflammatory bowel disease (IBD) and other local intestinal diseases, Parkinson's disease, autism and other mental disorders.
, founded in 2017, is an AI-based micro-ecological pharmaceutical company.
It is learned that, unlike the traditional "cell-animal model-human" medical research and development path, unknown Jun adopted an innovative scientific research model and a unique drug research and development platform, combining "artificial intelligence and bioinfocus analysis technology" with intestinal micro-ecological technology, in order to greatly improve the efficiency and success rate of new drug research and development.
, the company has established a bio-information analysis platform and a transformation and production platform to connect the entire link from "data" to "drug" to achieve a complete closure of micro-ecological drug development.
4, the reason for the list: Is China's rare drug research and development company with a sound small nucleic acid innovative drug research and development platform, is China's small nucleic acid technology and small nucleic acid pharmaceutical industry, the main pioneer, has established a cover of cardiovascular, tumor, metabolism, viral infection, optic neuropathy and other diseases in the field of small nucleic acid drug research and development pipeline.
, small nucleic acid therapy is one of the most popular research and development directions in the field of biomedicine.
small nucleic acid (siRNA) is an effect molecule of RNA interference that can have a powerful gene silencing effect in a variety of cells and tissues, including humans.
, the therapy is considered a breakthrough new class of drugs that offer precision treatments while providing a wide range of applicability.
founded in 2007, rebo Bio is dedicated to the research and development of small nucleic acid drugs.
awards speech, Rebo Bio has three small nucleic acid drugs in clinical trials: QPI-1007 for optic nerve protection, ISIS 449884 for type 2 diabetes, and ISIS 560131 for metastatic degenerative prostate cancer.
the study of NAION (non-arteritis front isothermic optic neuropathy) adaptation has entered clinical phase 3.
5, Bo Ya Series For reasons on the list: the transformative gene editing therapy leader, committed to high-quality gene editing technology into innovative therapies, this year submitted the first China National Drug Administration Drug Review Center (CDE) accepted the application for clinical trials of gene editing therapy.
founded in 2015,
is a biopharmaceutical company dedicated to accelerating drug research and developing innovative therapies for a wide range of genetic diseases and cancers through cutting-edge genomic editing technologies.
, Boya announced that CDE had accepted a clinical trial application for its gene-editing therapy ET-01.
ET-01 is an introphy CD34 plus hematocyte injection modified by the CRISPR/Cas9 gene-modified BCL11A red line enhancer, which is intended to be developed for transfusion-dependent type β thremia.
according to an earlier press release issued by Boya, there are as many as 30 million people living with thalassemia genes in China and 300,000 people with medium to severe thalassemia.
, there are still huge unsealed medical β with blood transfusion-dependent patients with thalassemia.
clinical trial submitted to CDE to evaluate the safety and effectiveity of ET-01 single transplants in patients with blood transfusion-dependent β thremia.
a press release that Boya's gene-editing therapy is expected to give blood transfusion-dependent β-thalassemia patients hope of a one-time cure.
6, Fuxing medicine on the list reasons: the first candidate mRNA new crown vaccine product BNT162b2 has been approved by China's State Drug Administration (NMPA) clinical trials.
This is a globally cooperative new crown vaccine product based on BioNTech's mRNA technology platform in Germany, and Fosun Pharma has exclusive development and commercial interest in the product in Greater China, including Chinese mainland, Hong Kong, Macau and Taiwan.
November 13, Fosun Pharma and BioNTech jointly announced that the new coronavirus mRNA candidate vaccine BNT162b2 has been approved for clinical trials in China.
BNT162b2 is a preventive biological product, mainly used in 18-85 years old people to prevent new coronavirus pneumonia.
, the vaccine is currently in Phase 3 clinical trials in the United States, Germany, Argentina, Brazil, South Africa and Turkey.
July, the vaccine was granted fast-track status by the FDA.
press release, the global Phase 3 clinical study of the BNT162b2 new crown candidate vaccine has been completed and has reached all major effectiveness endpoints.
analysis shows that 28 days after the first vaccination, the vaccine has a 95 percent effectiveness in preventing new coronavirus, reaching the FDA's requirements for emergency use authorization (EUA) security data milestones.
last night (November 20), Pfizer and BioNTech announced that they had filed an emergency authorization (EUA) application for BNT162b2 with the FDA.
7, the reasons for the list: self-study innovative CD47 antibody lemzoparlimab (TJC4) can reduce the binding with normal red blood cells, avoid the clinical trials commonly found in severe anemia and other toxic side effects, and the beginning of clinical efficacy.
also has the world's first long-acting human recombinant nalcombination 7, clinically leading humanized B7-H3 antibody enoblituzumab and a total of 18 pipelines in research.
research and development of innovative biological drugs in the field of cancer-focused tumor immunity and autoimmune diseases.
Lemzoparlimab is a highly differentiated CD47 monoclonal antibody developed by the company that, through a unique antigen binding table, minimizes binding to normal red blood cells while retaining a strong binding capacity with tumor cells, thus avoiding the severe anemia and other toxic side effects common in clinical trials of similar CD47 antibodies.
in a U.S. Phase 1 clinical study on the use of lemzoparlimab for the treatment of recurring or resuscable solid tumors and lymphomas, candidate drugs showed differentiated safety and pharmacodynamic advantages, as well as initial efficacy in treating solid tumors.
September, AbbVie 2003 3 billion U.S. dollars in a partnership with Tianwei to license the development and commercialization of lemzoparlimab in countries and regions outside Greater China.
addition, Tianyuan also has product lines including CD38 antibody TJ202, humanized B7-H3 antibody enoblituzumab, long-acting human recombinant white melatonin 7 (IL-7) TJ107, differentiated albino 6 (IL-6) signal path inhibitor TJ301, differentiated long-acting recombinant growth hormone TJ101, etc.
8, Fosun Kait's reasons for the list: As a joint venture between Fosun Pharma and Gilead Sciences' Kite Pharma, Fosun Kate not only rapidly promoted the world's first approved CAR-T therapy Yescarta for the treatment of large B-cell lymphoma in China, but also established a commercial production base for GMP, submitting new drug listing applications and obtaining priority reviews.
, founded in 2017, is dedicated to the industrialization and standardization of cancer immunocellular therapy technology.
Yescarta is an auto-CAR-T cell therapy product that targets CD19.
introduced Yescarta technology from Kite Pharma in 2017 and was authorized to localize production in China, naming it Aquilonsai Injection (FKC876).
Yescarta has been approved in the United States to treat adult patients with relapsed/re treatable large B-cell lymphoma, and in Europe approved to treat relapsed/resuscable diffuse large B-cell lymphoma (DLBCL) and primary vertical B-cell lymphoma.
February 2020, NMPA officially accepted a new drug listing application for Aquilansai injections for the treatment of adult patients with relapsed or resuscable large B-cell lymphoma after second-line or above systemic treatment.
, the application has been included in the CDE's priority review.
public information, the product is the first CAR-T cell therapy product that NMPA has officially accepted for listing.
in addition to the above-mentioned companies, this year's "50 smart companies" list of MIT Science and Technology Review also includes a number of biomedical companies, including stone-burning medicine, Panshengzi, micro-medical group, Meirui Medical, etc., limited to space, this article is no longer introduced.
congratulate these companies on their success and hope that these rising "smart companies" will make more progress and breakthroughs in the future and contribute to the development of science and technology and social progress.
: 1. Authoritative release: MIT Technology Review 50 smart companies list! In the post-epidemic era, focus on China . Retrieved Aug 19, 2020, from #wechat_redirect β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved Oct 27, 2020, from the company press release and announcement original title: MIT's annual "50 smart companies" were announced, Baiji Shenzhou, Xinda Bio, Fosun Pharma, Tianyuan Bio and other companies on the list! Follow Medicinal Mingkangde on WeChat Public No